Not exact matches
The team chose to compare breast tissue from healthy individuals with
tumor samples taken from breast cancer patients — including both primary
tumors that had not spread from the breast to other body sites, and highly
aggressive, metastatic
tumors.
Answering important clinical questions — such as whether genetic diversity is a risk factor for
aggressive tumor development or how it relates to treatment resistance — requires analyzing
samples from many patients with different types of cancer.
Since completing the initial paper published Thursday, the team has analyzed 50 more
samples from eye fluid of retinoblastoma patients, including those with less
aggressive tumors whose eyes were saved, to get a start on determining what factors might be at play in
tumor progression.